Media releases – Page 3 – 昱展新藥生技股份有限公司

2023/08/21 ALA-3000 has received the Notice of Eligibility of Grant from Intellectual Property Office of Singapore (IPOS) after the examination.(Patent Application No. 11202104792S)

Comments Off

23 . 8 . 2023

2023/08/07 ALA-3000 has received an Resolution of acceptance to registration from Instituto Nacional de Propiedad Industrial (INAPI)-Chile after the examination. (Patent Application No. 202101803)

Comments Off

10 . 8 . 2023

2023/08/02 ALA-3000 has received an Intention to Grant (IGRA) from European Patent Office (EPO) after examination. (Patent Application No. 20739053.5)

Comments Off

10 . 8 . 2023

2023/07/25 ALA-3000 Received the patent, KETAMINE PAMOATE AND USE THEREOF from China National Intellectual Property Administration (CNIPA) , NO : 202080007207.5

Comments Off

26 . 7 . 2023

2023/07/19 ALA-1300 Received the patent, LONG-ACTING INJECTABLE FORMULATIONS AND CRYSTALLINE FORMS OF BUPRENORPHINE DERIVATIVES , from Directorate General of Intellectual Property Rights (DGIP) of Indonesia, NO IDP 000 087828 B

Comments Off

26 . 7 . 2023

2023/06/29 ALA-1000 Received the patent, SUSTAINED-RELEASE BUPRENORPHINE FORMULATIONS, from Intellectual Property Corporation of Malaysia (MyIPO) , NO : MY-196269-A

Comments Off

30 . 6 . 2023